Advanced Nanomaterials for Preparedness Against (Re-)Emerging Viral Diseases
- PMID: 33586180
- DOI: 10.1002/adma.202005927
Advanced Nanomaterials for Preparedness Against (Re-)Emerging Viral Diseases
Abstract
While the coronavirus disease (COVID-19) accounts for the current global pandemic, the emergence of other unknown pathogens, named "Disease X," remains a serious concern in the future. Emerging or re-emerging pathogens continue to pose significant challenges to global public health. In response, the scientific community has been urged to create advanced platform technologies to meet the ever-increasing needs presented by these devastating diseases with pandemic potential. This review aims to bring new insights to allow for the application of advanced nanomaterials in future diagnostics, vaccines, and antiviral therapies, thereby addressing the challenges associated with the current preparedness strategies in clinical settings against viruses. The application of nanomaterials has advanced medicine and provided cutting-edge solutions for unmet needs. Herein, an overview of the currently available nanotechnologies is presented, highlighting the significant features that enable them to control infectious diseases, and identifying the challenges that remain to be addressed for the commercial production of nano-based products is presented. Finally, to conclude, the development of a nanomaterial-based system using a "One Health" approach is suggested. This strategy would require a transdisciplinary collaboration and communication between all stakeholders throughout the entire process spanning across research and development, as well as the preclinical, clinical, and manufacturing phases.
Keywords: antiviral therapeutics; diagnostic tools; emerging viral diseases; nanomaterials; nanovaccines.
© 2021 Wiley-VCH GmbH.
References
-
- World Health Organization, Archived: WHO Timeline - COVID-19, https://www.who.int/news/item/27-04-2020-who-timeline---covid-19 (accessed: October 2020).
-
- Y. H. Martin, How DO SARS and MERS Compared with COVID-19?, https://www.medicalnewstoday.com/articles/how-do-sars-and-mers-compare-w... (accessed: October 2020).
-
- M. S. Mehand, F. Al-Shorbaji, P. Millett, B. Murgue, Antiviral Res. 2018, 159, 63.
-
- D. Vijaykrishna, G. J. Smith, O. G. Pybus, H. Zhu, S. Bhatt, L. L. Poon, S. Riley, J. Bahl, S. K. Ma, C. L. Cheung, R. A. P. M. Perera, H. Chen, K. F. Shortridge, R. J. Webby, R. G. Webster, Y. Guan, J. S. M. Peiris, Nature 2011, 473, 519.
-
- C. Ke, C. K. P. Mok, W. Zhu, H. Zhou, J. He, W. Guan, J. Wu, W. Song, D. Wang, J. Liu, Q. Lin, D. K. W. Chu, L. Yang, N. Zhong, Z. Yang, Y. Shu, J. S. M. Peiris, Emerging Infect. Dis. 2017, 23, 1332.
Publication types
MeSH terms
Substances
Grants and funding
- 2020R1F1A1066247/National Research Foundation of Korea
- Basic Science Research Program
- NRF2018R1C1B6005424/NRF
- Center for BioNano Health Guard
- Ministry of Science and ICT
- 2014M3A6B2060507/H-GUARD
- KRIBB
- Research Initiative Program
- NRF-2019M3A9D5A01102797/Korea Mouse Phenotyping Project
- Ministry of Science, ICT and Future Planning
- National Research Foundation
- Bio & Medical Technology Development Programs
- NRF-2018M3A9H4056340/MSIT
- NRF-2018M3A9E2022819/MSIT
- Nano Material Technology Development Program
- 2017M3A7B4041798/Ministry of Education, Science and Technology
- National Research Foundation of Korea
- 2020R1F1A1066247/Korea government
- Ministry of Science, ICT
- NRF
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical